Kalaris Therapeutics, Inc.

Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.

KLRS | NDAQ

Overview

Corporate Details

ISIN(s):: US0198181036
LEI:
Country:: United States of America
Address:: 628 MIDDLEFIELD ROAD, 94301 PALO ALTO
Website:: https://kalaristx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for prevalent retinal diseases. The company's lead product candidate is TH103, a fully humanized, recombinant fusion protein designed as a next-generation anti-VEGF agent for intravitreal delivery. Co-developed by Dr. Napoleone Ferrara, known for his work on Avastin and Lucentis, TH103 acts as a soluble decoy receptor. A key feature is its high affinity for heparan sulfate proteoglycans (HSPG), which may act as a molecular anchor to extend its intraocular retention. This mechanism aims to reduce the frequency of injections for patients with neovascular retinal diseases, such as age-related macular degeneration.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kalaris Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kalaris Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Kalaris Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Esperion Therapeutics, Inc. Develops oral ACLY inhibitors to lower high LDL-C and cardiovascular risk.	United States of America	ESPR
ESSA Pharma Inc. Develops novel small molecule drugs to treat castration-resistant prostate cancer.	United States of America	EPIX
Estrella Immunopharma, Inc. Clinical-stage biopharma developing ARTEMIS® T-cell therapies for cancer & autoimmune disease.	United States of America	ESLA
Eton Pharmaceuticals, Inc. Develops and commercializes innovative treatments for rare pediatric diseases.	United States of America	ETON
EuBiologics Co., Ltd. Develops vaccines for global public health and provides biopharmaceutical CRMO services.	South Korea	206650
EUPRAXIA PHARMACEUTICALS INC. Developing targeted, extended-release therapies for GI and musculoskeletal diseases.	United States of America	EPRX
EuroAPI Global manufacturer of APIs and CDMO services for human and animal health partners worldwide.	France	EAPI
Eurobio Scientific Develops & distributes specialty IVD tests for oncology, transplant & infectious diseases.	France	ALERS
European Institute of Science AB Manufactures diagnostic assays and point-of-care instruments for the veterinary health market.	Sweden	EURI B
Evoke Pharma Inc Develops and commercializes a nasal spray for diabetic gastroparesis symptom relief.	United States of America	EVOK